Santtu H.
- Country
- Finland
- Department
- FVR - Helsinki South Clinic
Research Overview
- A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease
- Evaluation of Immune Response and Safety of rMenB+OMV NZ Vaccine in Adolescents and Young Adults Previously Primed for Invasive Meningococcal Disease
Data & Insights
Has run more than one trial at 3 of 46 partner sites.
Specializations
Respiratory Disease Prevention
This investigator specializes in the prevention of respiratory syncytial virus (RSV) infections, with particular focus on protecting vulnerable pediatric populations.
- Preventive Medicine in Pediatrics
- High-Risk Infant Care
- Viral Infection Prevention
The investigator's work centers on evaluating protective measures for infants and children who face increased risk of severe respiratory disease.
Pediatric Immunology
The investigator focuses on immunological interventions in pediatric populations, specifically studying protective antibody treatments for respiratory infections.
- Antibody-Based Therapeutics
- Pediatric Immune Protection
- Preventive Immunology
Their research examines innovative approaches to enhance immune protection in vulnerable pediatric patients.
Clinical Safety Assessment
The investigator specializes in evaluating the safety and tolerability of preventive treatments for respiratory conditions in pediatric populations.
- Safety Profile Analysis
- Therapeutic Monitoring
- Adverse Event Assessment
Their work involves comprehensive evaluation of therapeutic interventions in pediatric respiratory medicine.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.